Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
about
Ceramide synthases at the centre of sphingolipid metabolism and biologyMammalian ceramide synthasesA critical role for ceramide synthase 2 in liver homeostasis: II. insights into molecular changes leading to hepatopathyModulation of Autophagy by Sorafenib: Effects on Treatment Responsec-FLIP, a master anti-apoptotic regulatorSorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cellsSorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.Autophagy and cancer therapy.The pleiotropic roles of sphingolipid signaling in autophagyAutophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy.A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum.Interdiction of sphingolipid metabolism to improve standard cancer therapies.Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.Bcl2L13 is a ceramide synthase inhibitor in glioblastoma.Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment.Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy.Expression of Ceramide Synthase 6 Transcriptionally Activates Acid Ceramidase in a c-Jun N-terminal Kinase (JNK)-dependent MannerCombination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.Identification of initial leads directed at the calmodulin-binding region on the Src-SH2 domain that exhibit anti-proliferation activity against pancreatic cancerEndogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.By activating Fas/ceramide synthase 6/p38 kinase in lipid rafts, stichoposide D inhibits growth of leukemia xenografts.Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signalingSynergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.Phase I study of pemetrexed with sorafenib in advanced solid tumors.Recently identified and potential targets for colon cancer treatment.Autophagy and tumorigenesis.The neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors.Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors.Regulation of autophagy by kinases.PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression.Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells.Natural Bcl-2 inhibitor (-)- gossypol induces protective autophagy via reactive oxygen species-high mobility group box 1 pathway in Burkitt lymphoma.Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer.Calmodulin mediates Fas-induced FADD-independent survival signaling in pancreatic cancer cells via activation of Src-extracellular signal-regulated kinase (ERK).Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins.Evaluation of metastatic and angiogenic potentials of human colon carcinoma cells in chick embryo model systems.
P2860
Q24609859-FA509085-074A-4166-BE6B-B48CAD345A0BQ24633453-55ACBA67-056C-4AEB-B167-A7604A63777CQ24634622-40839F9E-2C77-4A12-927F-972B7B41E879Q26745320-1DBE14EC-364F-4D2E-917E-3AEB6AFF040AQ28391119-CDA43C8A-8168-4BED-ACDE-4521CBFCD353Q28533484-69B95DC2-715D-4097-BEE1-2D7A443539AAQ33576187-F986B67C-6F2E-40DF-84EB-EF595BAEC330Q33584607-585B5B11-D768-4269-B933-A374AEAE9660Q33720239-091902D4-9E65-4EB8-848B-E65555E38EEBQ33839054-19A190F5-79D3-4817-B804-2A9C1C855FC4Q34179998-6D111B37-12E3-4BAA-B89A-AE252CC125A2Q34373466-C0E7F019-9085-4E46-AF05-051735163164Q34399444-2CAAC107-C5E8-4DD1-9A12-7B1AA04EAF05Q34413943-DB496829-716C-4D19-9536-56CA2124FEE9Q35113327-79CA10D7-D3F4-4BA8-867F-7C16004A9818Q35227285-BA5FA520-D84E-44AC-ABE3-36999B365B1BQ35762274-98D060DB-098B-4044-BB77-15B929E70CFBQ35860939-A05C251E-EA24-4267-A23B-CB26C73B5364Q35895346-D19349CC-CC44-4765-8B87-AED18424FE86Q35902399-2BA86CA6-A04D-41A5-8E72-35C759F03D5CQ35975127-5E78C7E0-4FF3-4AAC-B1A3-5B664BC3476CQ36413845-9A22B5DF-A7A3-42AF-BB17-C333459604DFQ36919811-3869D94C-C6FB-4940-9C48-1A6E35C3A950Q37040669-D0C76FF6-D51F-4A55-B59F-568485669CD2Q37520649-C974582D-D2EE-4AE0-9A0C-9BFDC4E97C92Q37763104-3D7D7E7E-D8C6-46F5-A278-4B00F7E31A4CQ37768714-1064B351-25A3-4E83-A786-6431F1D77BB1Q37821836-088FE589-59D1-4C79-9EA4-8D05F8095F15Q37863629-21DBB366-066A-465C-90D8-E259B759FB8FQ38161364-78F6FA1C-2107-49F0-AFFA-213D7C1D545DQ38721255-9CE0B670-706F-4081-A4AD-4BF32D816305Q38921009-290E61D5-AFAE-4AB2-84EC-129E2116FAEAQ39165456-5AB813A4-598C-4A38-AE35-E6B5D1A33553Q39196767-DC92650F-3295-4709-AB67-D342D8747845Q39202496-1062F0D7-ACC7-439D-85F2-BEE07443648AQ39420607-EBFF0FF8-D3AE-4CFF-B3E9-3B37FCF0F3D2Q39536531-F406BB26-C209-45A5-9B5D-0BD869DDA051Q39680200-7C66FA57-F430-4D18-9990-7F688355BAC7Q39747108-A9BFE1F3-7174-4A74-85F1-921B370C6076Q39785586-982EC0D8-3D5F-4ADA-A42F-9884F54D589E
P2860
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sorafenib and vorinostat kill ...... t and -independent mechanisms.
@en
Sorafenib and vorinostat kill ...... t and -independent mechanisms.
@nl
type
label
Sorafenib and vorinostat kill ...... t and -independent mechanisms.
@en
Sorafenib and vorinostat kill ...... t and -independent mechanisms.
@nl
prefLabel
Sorafenib and vorinostat kill ...... t and -independent mechanisms.
@en
Sorafenib and vorinostat kill ...... t and -independent mechanisms.
@nl
P2093
P2860
P356
P1476
Sorafenib and vorinostat kill ...... t and -independent mechanisms.
@en
P2093
Adly Yacoub
Christina Voelkel-Johnson
Clint Mitchell
Margaret A Park
Martin Graf
Mohamed Rahmani
Peter J Houghton
Steven Grant
Teneille Walker
P2860
P304
P356
10.1124/MOL.109.056523
P50
P577
2009-05-29T00:00:00Z